These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34420881)

  • 1. Sero-prevalence of SARS-CoV-2 antibodies in blood donors during the third wave of infection in Norway, winter/spring 2021.
    Hvalryg M; Nissen-Meyer LSH
    Transfus Apher Sci; 2021 Oct; 60(5):103256. PubMed ID: 34420881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
    Charlton CL; Nguyen LT; Bailey A; Fenton J; Plitt SS; Marohn C; Lau C; Hinshaw D; Lutsiak C; Simmonds K; Kanji JN; Zelyas N; Lee N; Mengel M; Tipples G
    Microbiol Spectr; 2021 Sep; 9(1):e0029121. PubMed ID: 34406813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History.
    Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF
    Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 seroprevalence among blood donors in Québec, and analysis of symptoms associated with seropositivity: a nested case-control study.
    Lewin A; Therrien R; De Serres G; Grégoire Y; Perreault J; Drouin M; Fournier MJ; Tremblay T; Beaudoin J; Beaudoin-Bussières G; Prévost J; Gendron-Lepage G; Finzi A; Bernier F; Bazin R; Germain M; Delage G
    Can J Public Health; 2021 Aug; 112(4):576-586. PubMed ID: 33999398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021.
    Jones JM; Stone M; Sulaeman H; Fink RV; Dave H; Levy ME; Di Germanio C; Green V; Notari E; Saa P; Biggerstaff BJ; Strauss D; Kessler D; Vassallo R; Reik R; Rossmann S; Destree M; Nguyen KA; Sayers M; Lough C; Bougie DW; Ritter M; Latoni G; Weales B; Sime S; Gorlin J; Brown NE; Gould CV; Berney K; Benoit TJ; Miller MJ; Freeman D; Kartik D; Fry AM; Azziz-Baumgartner E; Hall AJ; MacNeil A; Gundlapalli AV; Basavaraju SV; Gerber SI; Patton ME; Custer B; Williamson P; Simmons G; Thornburg NJ; Kleinman S; Stramer SL; Opsomer J; Busch MP
    JAMA; 2021 Oct; 326(14):1400-1409. PubMed ID: 34473201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of US Blood Donors Testing Reactive for Antibodies to SARS-CoV-2 Prior to the Availability of Authorized Vaccines.
    Dodd RY; Spencer BR; Xu M; Foster GA; Saá P; Brodsky JP; Stramer SL
    Transfus Med Rev; 2021 Jul; 35(3):1-7. PubMed ID: 34373145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating SARS-CoV-2 Seroprevalence in Canadian Blood Donors, April 2020 to March 2021: Improving Accuracy with Multiple Assays.
    Tuite AR; Fisman D; Abe KT; Rathod B; Pasculescu A; Colwill K; Gingras AC; Yi QL; O'Brien SF; Drews SJ
    Microbiol Spectr; 2022 Feb; 10(1):e0256321. PubMed ID: 35196819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seroprevalence of Anti-SARS-CoV-2 Antibodies in Blood Donors from Nuevo Leon State, Mexico, during 2020: A Retrospective Cross-Sectional Evaluation.
    Martinez-Acuña N; Avalos-Nolazco DM; Rodriguez-Rodriguez DR; Martinez-Liu CG; Galan-Huerta KA; Padilla-Rivas GR; Ramos-Jimenez J; Ayala-de-la-Cruz S; Cienfuegos-Pecina E; Diaz-Chuc EA; Cazares-Tamez R; Flores-Arechiga A; Perez-Chavez F; Arellanos-Soto D; Lozano-Sepulveda SA; Garza-Gonzalez E; Treviño-Garza C; Montes-de-Oca-Luna R; Lee-Gonzalez AB; de-la-O-Cavazos ME; Rivas-Estilla AM
    Viruses; 2021 Jun; 13(7):. PubMed ID: 34202849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].
    Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F;
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seropositivity in blood donors and pregnant women during the first year of SARS-CoV-2 transmission in Stockholm, Sweden.
    Castro Dopico X; Muschiol S; Christian M; Hanke L; Sheward DJ; Grinberg NF; Rorbach J; Bogdanovic G; Mcinerney GM; Allander T; Wallace C; Murrell B; Albert J; Karlsson Hedestam GB
    J Intern Med; 2021 Sep; 290(3):666-676. PubMed ID: 34008203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada.
    Saeed S; Drews SJ; Pambrun C; Yi QL; Osmond L; O'Brien SF
    Transfusion; 2021 Mar; 61(3):862-872. PubMed ID: 33527398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study: an observational cohort study of SARS-CoV-2 infection and vaccination in healthcare workers.
    Jackson-Thompson BM; Goguet E; Laing ED; Olsen CH; Pollett S; Hollis-Perry KM; Maiolatesi SE; Illinik L; Ramsey KF; Reyes AE; Alcorta Y; Wong MA; Davies J; Ortega O; Parmelee E; Lindrose AR; Moser M; Graydon E; Letizia AG; Duplessis CA; Ganesan A; Pratt KP; Malloy AM; Scott DW; Anderson SK; Snow AL; Dalgard CL; Powers JH; Tribble D; Burgess TH; Broder CC; Mitre E
    BMC Infect Dis; 2021 Jun; 21(1):544. PubMed ID: 34107889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan.
    Valenti L; Bergna A; Pelusi S; Facciotti F; Lai A; Tarkowski M; Lombardi A; Berzuini A; Caprioli F; Santoro L; Baselli G; Ventura CD; Erba E; Bosari S; Galli M; Zehender G; Prati D;
    Blood Transfus; 2021 May; 19(3):181-189. PubMed ID: 33539289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression and Predictors of SARS-CoV-2 Antibody Seroreactivity In US Blood Donors.
    Vassallo RR; Dumont LJ; Bravo MD; Hazegh K; Kamel H
    Transfus Med Rev; 2021 Jul; 35(3):8-15. PubMed ID: 34376289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-SARS-CoV-2 antibody among SARS-CoV-2 vaccinated vs post-infected blood donors in a tertiary hospital, Bangkok, Thailand.
    Permpikul P; Tongyoo S; Chaimayo C; Kanpai P; Virat J; Virat S; Chuchaaim J; Thongput A; Bhatnagar S
    PLoS One; 2023; 18(5):e0285737. PubMed ID: 37200273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020.
    Thompson CP; Grayson NE; Paton RS; Bolton JS; Lourenço J; Penman BS; Lee LN; Odon V; Mongkolsapaya J; Chinnakannan S; Dejnirattisai W; Edmans M; Fyfe A; Imlach C; Kooblall K; Lim N; Liu C; López-Camacho C; McInally C; McNaughton AL; Ramamurthy N; Ratcliff J; Supasa P; Sampson O; Wang B; Mentzer AJ; Turner M; Semple MG; Baillie K; ; Harvala H; Screaton GR; Temperton N; Klenerman P; Jarvis LM; Gupta S; Simmonds P
    Euro Surveill; 2020 Oct; 25(42):. PubMed ID: 33094713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic.
    Dickson E; Palmateer NE; Murray J; Robertson C; Waugh C; Wallace LA; Mathie L; Heatlie K; Mavin S; Gousias P; Von Wissman B; Goldberg DJ; McAuley A
    Public Health; 2021 Jan; 190():132-134. PubMed ID: 33453689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study.
    Trieu MC; Bansal A; Madsen A; Zhou F; Sævik M; Vahokoski J; Brokstad KA; Krammer F; Tøndel C; Mohn KGI; Blomberg B; Langeland N; Cox RJ;
    J Infect Dis; 2021 Feb; 223(4):589-599. PubMed ID: 33247924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic.
    Popova AY; Smirnov VS; Andreeva EE; Babura EA; Balakhonov SV; Bashketova NS; Bugorkova SA; Bulanov MV; Valeullina NN; Vetrov VV; Goryaev DV; Detkovskaya TN; Ezhlova EB; Zaitseva NN; Istorik OA; Kovalchuk IV; Kozlovskikh DN; Kombarova SY; Kurganova OP; Lomovtsev AE; Lukicheva LA; Lyalina LV; Melnikova AA; Mikailova OM; Noskov AK; Noskova LN; Oglezneva EE; Osmolovskaya TP; Patyashina MA; Penkovskaya NA; Samoilova LV; Stepanova TF; Trotsenko OE; Totolian AA
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hidden fraction of Polish population immune to SARS-CoV-2 in May 2021.
    Budziar W; Gembara K; Harhala M; Szymczak A; Jędruchniewicz N; Baniecki K; Pikies A; Nahorecki A; Hoffmann A; Kardaś A; Szewczyk-Dąbrowska A; Klimek T; Kaźmierczak Z; Witkiewicz W; Barczyk K; Dąbrowska K
    PLoS One; 2022; 17(2):e0253638. PubMed ID: 35113873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.